AstraZeneca : Canada Approves Ultomiris For Adults With Neuromyelitis Optica Spectrum Disorder

(RTTNews) - AstraZeneca plc. (AZN.L, AZN) said that Health Canada approved Ultomiris (ravulizumab) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum dis https://www.nasdaq.com/articles/astrazeneca-:-canada-approves-ultomiris-for-adults-with-neuromyelitis-optica-spectrum